IL158558A0 - Antiviral compounds - Google Patents

Antiviral compounds

Info

Publication number
IL158558A0
IL158558A0 IL15855802A IL15855802A IL158558A0 IL 158558 A0 IL158558 A0 IL 158558A0 IL 15855802 A IL15855802 A IL 15855802A IL 15855802 A IL15855802 A IL 15855802A IL 158558 A0 IL158558 A0 IL 158558A0
Authority
IL
Israel
Prior art keywords
antiviral compounds
treatment
esters
flaviviruses
hcv
Prior art date
Application number
IL15855802A
Other languages
English (en)
Original Assignee
Virogen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virogen Ltd filed Critical Virogen Ltd
Publication of IL158558A0 publication Critical patent/IL158558A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL15855802A 2001-05-03 2002-05-02 Antiviral compounds IL158558A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0110832.3A GB0110832D0 (en) 2001-05-03 2001-05-03 Antiviral compounds
PCT/EP2002/004944 WO2002089780A2 (en) 2001-05-03 2002-05-02 Antiviral compounds

Publications (1)

Publication Number Publication Date
IL158558A0 true IL158558A0 (en) 2004-05-12

Family

ID=9913938

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15855802A IL158558A0 (en) 2001-05-03 2002-05-02 Antiviral compounds
IL158558A IL158558A (en) 2001-05-03 2003-10-23 Use of castanospherin esters for the preparation of drugs for the treatment of inflammation caused by the hepatitis C virus, preparations containing castanospermin esters, their use and kits containing them

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL158558A IL158558A (en) 2001-05-03 2003-10-23 Use of castanospherin esters for the preparation of drugs for the treatment of inflammation caused by the hepatitis C virus, preparations containing castanospermin esters, their use and kits containing them

Country Status (19)

Country Link
US (1) US7601735B2 (cg-RX-API-DMAC7.html)
EP (1) EP1387681B1 (cg-RX-API-DMAC7.html)
JP (2) JP2004527566A (cg-RX-API-DMAC7.html)
KR (1) KR100660241B1 (cg-RX-API-DMAC7.html)
CN (1) CN100428936C (cg-RX-API-DMAC7.html)
AT (1) ATE405261T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002341155B2 (cg-RX-API-DMAC7.html)
CA (1) CA2445271A1 (cg-RX-API-DMAC7.html)
CY (1) CY1110437T1 (cg-RX-API-DMAC7.html)
DE (1) DE60228436D1 (cg-RX-API-DMAC7.html)
DK (1) DK1387681T3 (cg-RX-API-DMAC7.html)
ES (1) ES2312587T3 (cg-RX-API-DMAC7.html)
GB (1) GB0110832D0 (cg-RX-API-DMAC7.html)
IL (2) IL158558A0 (cg-RX-API-DMAC7.html)
NO (1) NO326292B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ529448A (cg-RX-API-DMAC7.html)
PT (1) PT1387681E (cg-RX-API-DMAC7.html)
WO (1) WO2002089780A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200308483B (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0116643D0 (en) * 2001-07-09 2001-08-29 Virogen Ltd Antiviral compounds
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
WO2006085141A2 (en) * 2004-08-13 2006-08-17 Migenix Inc. Compositions and methods for treating or preventing hepadnaviridae infection
CA2583351A1 (en) * 2004-10-06 2006-04-13 Migenix Inc. Combination anti-viral compositions comprising castanospermine and methods of use
AU2006221080A1 (en) * 2005-02-09 2006-09-14 Migenix Inc. Compositions and methods for treating or preventing flaviviridae infections
JP2007297289A (ja) * 2006-04-27 2007-11-15 Kitasato Gakuen 抗ウイルス剤
CA2666814A1 (en) * 2006-08-21 2008-05-29 United Therapeutics Corporation Combination therapy for treatment of viral infections
KR101314166B1 (ko) * 2011-06-16 2013-10-04 건국대학교 산학협력단 석이버섯 가수분해 효소 추출물 또는 이로로부터 분리된 화합물을 유효성분으로 함유하는 항산화 조성물
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
CN102343083A (zh) * 2011-10-17 2012-02-08 中国科学院成都生物研究所 一种抗病毒的组合药物
AU2014228035B2 (en) * 2013-03-15 2018-12-06 60 Degrees Pharmaceuticals, Inc. Novel dosing regimens of celgosivir for the treatment of dengue
CA2924829C (en) 2013-09-27 2019-10-29 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as hiv integrase inhibitors
US10046005B2 (en) * 2014-02-07 2018-08-14 Shaker A. Mousa Composition and method of use for combinations of anti-viral protease, polymerase inhibitors and natural bioactive compounds in the treatment of hepatitis C infection
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
SG10201912141YA (en) * 2015-12-11 2020-02-27 60 Pharmaceuticals Llc Novel dosing regimens of celgosivir for the prevention of dengue
HRP20210847T1 (hr) 2016-03-31 2021-07-23 Janssen Pharmaceuticals, Inc. Supstituirani derivati indola kao inhibitori replikacije denga virusa
WO2017167953A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EA201892200A1 (ru) 2016-04-01 2019-03-29 Янссен Фармасьютикалз, Инк. Замещенные производные соединений индола в качестве ингибиторов репликации вирусов денге
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CA3060583C (en) 2017-05-22 2024-06-04 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
CR20190531A (es) 2017-05-22 2020-03-05 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
PH12022551160A1 (en) 2019-11-15 2023-09-25 Janssen Pharmaceuticals Inc Treatment and prevention of dengue disease
JP7497790B2 (ja) * 2019-12-27 2024-06-11 国立大学法人北海道大学 豚コレラの治療及び/又は予防剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1315276C (en) 1987-07-02 1993-03-30 Paul S. Liu Castanospermine esters and glycosides
US5004746A (en) 1987-09-29 1991-04-02 Merrell Dow Pharmaceuticals Inc. Anti-retroviral castanospermine esters
US4849430A (en) 1988-03-09 1989-07-18 Monsanto Company Method of inhibiting virus
US5017563A (en) * 1988-06-23 1991-05-21 Merrell Dow Pharmaceuticals Inc. Castanospermine esters and glycosides
US4970317A (en) 1989-08-08 1990-11-13 Merrell Dow Pharmaceuticals Inc. Process for the preparation of castanospermine esters
US5066807A (en) 1990-03-12 1991-11-19 Merrell Dow Pharmaceuticals Inc. Process for the preparation of castanospermine
US5093501A (en) 1990-03-12 1992-03-03 Merrell Dow Pharmaceuticals Inc. Intermediates in a process for the preparation of castanospermine
GB9027433D0 (en) 1990-12-18 1991-02-06 Merrell Dow Pharma Anti-herpes castanospermine esters
US5939430A (en) 1993-02-22 1999-08-17 Merrell Pharmaceuticals Inc. Combinations of retroviral inhibitors
GB9719189D0 (en) * 1997-09-09 1997-11-12 Glaxo Group Ltd New therapeutic method
US5959111A (en) 1997-05-22 1999-09-28 Hoechst Marion Roussel, Inc. Process for preparing 6-0-monoesters of castanospermine
AU761748B2 (en) * 1997-12-11 2003-06-12 Chancellor, Masters And Scholars Of The University Of Oxford, The Inhibition of membrane-associated viral replication
AU2001234596A1 (en) 2000-01-28 2001-08-07 Timothy M Block Use of castanospermine and substituted-castanospermine compounds for treating hepatitis virus infections

Also Published As

Publication number Publication date
GB0110832D0 (en) 2001-06-27
JP2005290015A (ja) 2005-10-20
ATE405261T1 (de) 2008-09-15
EP1387681A2 (en) 2004-02-11
NZ529448A (en) 2005-11-25
PT1387681E (pt) 2008-12-02
NO20034878L (no) 2003-12-22
AU2002341155B2 (en) 2007-10-18
WO2002089780A3 (en) 2003-03-06
IL158558A (en) 2011-09-27
CA2445271A1 (en) 2002-11-14
NO326292B1 (no) 2008-11-03
ZA200308483B (en) 2005-10-26
DK1387681T3 (da) 2009-01-05
CN100428936C (zh) 2008-10-29
NO20034878D0 (no) 2003-10-31
ES2312587T3 (es) 2009-03-01
HK1068538A1 (zh) 2005-04-29
US20040147549A1 (en) 2004-07-29
WO2002089780A2 (en) 2002-11-14
DE60228436D1 (de) 2008-10-02
JP2004527566A (ja) 2004-09-09
CN1516582A (zh) 2004-07-28
JP4406383B2 (ja) 2010-01-27
KR20040007527A (ko) 2004-01-24
US7601735B2 (en) 2009-10-13
EP1387681B1 (en) 2008-08-20
KR100660241B1 (ko) 2006-12-20
CY1110437T1 (el) 2015-04-29

Similar Documents

Publication Publication Date Title
GB0110832D0 (en) Antiviral compounds
MXPA02012443A (es) Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos.
EP1455809A4 (en) INHIBITORS OF HEPATITIS C VIRUSES
EA200701869A1 (ru) Пептидомиметические ингибиторы протеазы
YU98103A (sh) 4'-supstituisani nukleozidi
WO2006130627A3 (en) Methods for treating hepatitis c
DE50102597D1 (de) Arzneimittel gegen virale erkrankungen
TW200500373A (en) 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
PL376409A1 (en) Composition for the treatment of infection by flaviviridae viruses
UY27465A1 (es) Métodos y composiciones para tratar flavivirus y pestivirus con 4' modificaciones nucleosides
NO20025600D0 (no) Fremgangsmåter og sammensetninger for behandling av flavivirus og pestivirus
SV2005001920A (es) " compuestos nucleosidos para el tratamiento de infecciones virales "
MXPA03008623A (es) Combinacion farmaceutica para el tratamiento del cancer.
MXPA02011969A (es) Metodos para el tratamiento de padecimientos virales con il-18 y combinaciones de il-18.
TW200501940A (en) Virus therapeutic drug
AP2001002181A0 (en) Use of 17-ketosteroid compounds and derivatives, metabolites and precursors thereof in the treatment of hepatitis C virus and other toga viruses.
NZ528164A (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency
WO2004052905A3 (en) Antiviral nucleoside derivatives
UA95299C2 (ru) Профилактический или терапевтический агент против вирусного заболевания, вызванного вирусом гепатита с
PT1765370E (pt) Parapoxvirus em associação com outros agentes antivirais para o tratamento de hiv/sida
ATE366720T1 (de) Substituierte diarylharnstoffe als stimulatoren der fas-vermittelten apoptose
MXPA05007901A (es) Terapia de combinacion para hcv.
AU2003253888A8 (en) Combination therapies with l-fmau for the treatment of hepatitis b virus infection
WO2003006017A3 (en) Use of certain castanospermine esters in the treatment of influenza virus infections
PT1150981E (pt) Composto nucleosidico terapeutico

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed